Hantech Bio-Technology Co., Ltd. (TPEX:1294)
Taiwan
· Delayed Price · Currency is TWD 89.60
+2.40 (2.75%)
Mar 9, 2026, 1:30 PM CST
Hantech Bio-Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 717.85 | 748.42 | 625.14 | 302.52 | 240.29 | 266.69 | Upgrade
|
| Revenue Growth (YoY) | -9.79% | 19.72% | 106.65% | 25.90% | -9.90% | 130.17% | Upgrade
|
| Cost of Revenue | 448.95 | 442.68 | 344.29 | 175.89 | 139.27 | 140.36 | Upgrade
|
| Gross Profit | 268.9 | 305.74 | 280.85 | 126.63 | 101.03 | 126.33 | Upgrade
|
| Selling, General & Admin | 94.45 | 98.17 | 88.34 | 61.11 | 55.51 | 47.99 | Upgrade
|
| Research & Development | 11.16 | 10.13 | 7.37 | 8.09 | 6.9 | 5.37 | Upgrade
|
| Operating Expenses | 105.61 | 108.28 | 95.15 | 69.8 | 61.36 | 53.68 | Upgrade
|
| Operating Income | 163.29 | 197.47 | 185.71 | 56.84 | 39.67 | 72.65 | Upgrade
|
| Interest Expense | -3.03 | -5.38 | -2.12 | -1.47 | -1.55 | -1.02 | Upgrade
|
| Interest & Investment Income | 2.25 | 1.39 | 0.65 | 0.27 | 0.05 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.45 | 0.55 | -0.03 | 2.57 | -0.2 | -0.41 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.23 | 0.96 | 0.46 | 0.07 | 0.45 | -0.18 | Upgrade
|
| EBT Excluding Unusual Items | 163.19 | 194.99 | 184.68 | 58.28 | 38.42 | 71.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.35 | -0.11 | -0.55 | -0 | -1.1 | Upgrade
|
| Pretax Income | 163.19 | 194.64 | 184.57 | 57.73 | 38.42 | 69.97 | Upgrade
|
| Income Tax Expense | 30.81 | 39.22 | 37.04 | 11.87 | 7.33 | 14.31 | Upgrade
|
| Earnings From Continuing Operations | 132.38 | 155.42 | 147.53 | 45.86 | 31.09 | 55.66 | Upgrade
|
| Minority Interest in Earnings | 0.04 | 0.26 | 0.59 | 1.61 | 1.47 | 0.11 | Upgrade
|
| Net Income | 132.42 | 155.67 | 148.12 | 47.47 | 32.56 | 55.77 | Upgrade
|
| Net Income to Common | 132.42 | 155.67 | 148.12 | 47.47 | 32.56 | 55.77 | Upgrade
|
| Net Income Growth | -25.19% | 5.10% | 212.00% | 45.81% | -41.62% | 601.65% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 28 | 28 | 26 | 23 | 22 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 29 | 28 | 26 | 24 | 24 | Upgrade
|
| Shares Change (YoY) | 7.18% | 3.38% | 8.45% | 7.98% | 2.60% | 9.89% | Upgrade
|
| EPS (Basic) | 4.38 | 5.47 | 5.36 | 1.86 | 1.41 | 2.49 | Upgrade
|
| EPS (Diluted) | 4.32 | 5.32 | 5.23 | 1.82 | 1.35 | 2.37 | Upgrade
|
| EPS Growth | -30.09% | 1.74% | 188.00% | 34.69% | -43.04% | 540.52% | Upgrade
|
| Free Cash Flow | 162.43 | 126.13 | -102.03 | -19.7 | -34.87 | 7.23 | Upgrade
|
| Free Cash Flow Per Share | 5.29 | 4.31 | -3.60 | -0.76 | -1.44 | 0.31 | Upgrade
|
| Dividend Per Share | 2.907 | 2.907 | 0.699 | 0.608 | - | 0.349 | Upgrade
|
| Dividend Growth | 315.99% | 315.99% | 14.99% | - | - | 99.94% | Upgrade
|
| Gross Margin | 37.46% | 40.85% | 44.93% | 41.86% | 42.04% | 47.37% | Upgrade
|
| Operating Margin | 22.75% | 26.38% | 29.71% | 18.79% | 16.51% | 27.24% | Upgrade
|
| Profit Margin | 18.45% | 20.80% | 23.69% | 15.69% | 13.55% | 20.91% | Upgrade
|
| Free Cash Flow Margin | 22.63% | 16.85% | -16.32% | -6.51% | -14.51% | 2.71% | Upgrade
|
| EBITDA | 190.33 | 221.24 | 198.27 | 68.54 | 50.96 | 82.35 | Upgrade
|
| EBITDA Margin | 26.51% | 29.56% | 31.72% | 22.66% | 21.21% | 30.88% | Upgrade
|
| D&A For EBITDA | 27.05 | 23.77 | 12.56 | 11.71 | 11.29 | 9.71 | Upgrade
|
| EBIT | 163.29 | 197.47 | 185.71 | 56.84 | 39.67 | 72.65 | Upgrade
|
| EBIT Margin | 22.75% | 26.38% | 29.71% | 18.79% | 16.51% | 27.24% | Upgrade
|
| Effective Tax Rate | 18.88% | 20.15% | 20.07% | 20.56% | 19.09% | 20.45% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.